Zura Bio Ltd (ZURA) stock
ZURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.97−0.07 (-6.75%)
Close on Nov 18, 2026Market cap $92.96MP/E –Yield –
Zura Bio r&d expenses
Research and development expenses are spending on new products and technology.
Zura Bio's R&D Expenses for the twelve months ending Sep 30, 2026 was $65.90M, up 63.3% year over year. For fiscal 2025 it was $42.08M, up 72.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.08M | +72.5% |
| FY2024 | Dec 31, 2024 | $24.40M | -44.5% |
| FY2023 | Dec 31, 2023 | $44.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $19.49M | +63.1% |
| Q2 FY2026 | Jun 30, 2026 | $20.71M | +137.9% |
| Q1 FY2026 | Mar 31, 2026 | $14.75M | +40.8% |
| Q4 FY2025 | Dec 31, 2025 | $10.96M | +18.6% |
| Q3 FY2025 | Sep 30, 2025 | $11.95M | +98.2% |
| Q2 FY2025 | Jun 30, 2025 | $8.70M | +57.1% |
| Q1 FY2025 | Mar 31, 2025 | $10.47M | +191.5% |
| Q4 FY2024 | Dec 31, 2024 | $9.24M | +33.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.03M | +52.1% |
| Q2 FY2024 | Jun 30, 2024 | $5.54M | -80.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.59M | -26.4% |
| Q4 FY2023 | Dec 31, 2023 | $6.92M | +1567.5% |
| Q3 FY2023 | Sep 30, 2023 | $3.97M | +4564.7% |
| Q2 FY2023 | Jun 30, 2023 | $28.23M | – |
| Q1 FY2023 | Mar 31, 2023 | $4.88M | – |
| Q3 FY2022 | Sep 30, 2022 | $415.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $85.00K | – |
See a number that looks wrong?